Loading
Yanuki
BIOTECH FEED
AbbVie Acquires Capstan Therapeutics for $2.1 Billion to Advance In Vivo CAR-T Therapies | Sarepta Provides Safety Update for ELEVIDYS and Initiates Steps to Strengthen Safety | AbbVie Acquires Capstan Therapeutics for $2.1 Billion to Advance In Vivo CAR-T Therapies | Sarepta Provides Safety Update for ELEVIDYS and Initiates Steps to Strengthen Safety

Biotech / Deals

AbbVie Acquires Capstan Therapeutics for $2.1 Billion to Advance In Vivo CAR-T Therapies

AbbVie is expanding its presence in the cell and gene therapy space with the acquisition of Capstan Therapeutics. This deal, valued at $2.1 billion, will give AbbVie access to Capstan's novel in vivo CAR-T technology, which holds promise fo...

AbbVie Acquires Capstan Therapeutics for $2.1 Billion to Advance In Vivo CAR-T Therapies Image via Endpoints News
AbbVie bags Capstan’s in vivo CAR-T work with $2.1B buyout deal
Deals Gene Therapy